Compare CRNT & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNT | CVRX |
|---|---|---|
| Founded | 1996 | 2000 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.7M | 171.7M |
| IPO Year | 2000 | 2021 |
| Metric | CRNT | CVRX |
|---|---|---|
| Price | $2.31 | $8.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | $4.00 | ★ $11.20 |
| AVG Volume (30 Days) | ★ 423.1K | 416.5K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $56,651,000.00 |
| Revenue This Year | $8.91 | $16.78 |
| Revenue Next Year | $6.42 | $19.82 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.45 |
| 52 Week Low | $1.82 | $4.37 |
| 52 Week High | $2.84 | $13.34 |
| Indicator | CRNT | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.06 | 67.74 |
| Support Level | $2.24 | $8.42 |
| Resistance Level | $2.43 | $9.26 |
| Average True Range (ATR) | 0.11 | 0.70 |
| MACD | -0.00 | 0.32 |
| Stochastic Oscillator | 79.66 | 95.83 |
Ceragon Networks Ltd is a wireless transport company in terms of unit shipments and wide distribution of its business, providing high-capacity wireless connectivity solutions to markets across various industries, mainly wireless (mobile) networks service providers. Geographically the company generates the key revenue from India. The company also has presence in North America, Europe, Africa, Asia-Pacific and Middle East, and Latin America. The company's products include IP-50 Platform, IP-20 Platform, Pointlink.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.